CTLA4 and neoplasm: For example, therapeutic antibodies targeting T-cell inhibitory checkpoint proteins such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been demonstrated to be effective approaches to restore or enhance T-cell function and evoke a robust anti-tumor immune response [3].